Irbesartan Viatris (Irbesartan)

Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptors on blood vessels, adrenal glands and renal tissue. By preventing angiotensin II from binding, it inhibits vasoconstriction and aldosterone release, leading to vessel relaxation, reduced sodium‑water retention, and lower blood pressure.

The appropriate dose of Irbesartan Viatris is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and overall clinical profile. Dosage adjustments are made individually; no fixed regimen is provided here.

Safety of Irbesartan in pregnancy has not been established and the drug is generally contraindicated because of potential fetal toxicity. Use during breastfeeding is also not recommended unless the benefit outweighs the risk, and the prescriber should evaluate each case.

To order Irbesartan Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Irbesartan and ACE inhibitors target the renin‑angiotensin system, but Irbesartan blocks the AT1 receptor downstream of angiotensin II, whereas ACE inhibitors prevent its formation. Irbesartan is often better tolerated with a lower incidence of cough and angioedema, though both classes share risks of hyperkalemia and renal impairment.

Irbesartan Viatris tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Irbesartan Viatris is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious risks include angioedema (potentially life‑threatening swelling of the face, lips, tongue or airway), severe hyperkalemia, acute renal failure or worsening kidney function, and symptomatic hypotension, especially when combined with other antihypertensives.

Irbesartan should be avoided in patients with known hypersensitivity to the drug, in pregnancy, and in individuals with severe hepatic impairment. Caution is also advised for patients with existing renal dysfunction, high serum potassium, or those taking interacting medications without proper monitoring.